NSC23925 prevents the emergence of multidrug resistance in ovarian cancer in vitro and in vivo

Gynecologic Oncology

Volumn 137, Issue 1, 2015, Pages 134-142

  Yang, Xiaoqian ^a,b   Feng, Yong ^a   Gao, Yan ^a   Shen, Jacson ^a   Choy, Edwin ^a   Cote, Gregory ^a   Harmon, David ^a   Zhang, Zhan ^b   Mankin, Henry ^a   Hornicek, Francis J ^a   Duan, Zhenfeng ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

Multidrug resistance; NSC23925; Ovarian cancer; Paclitaxel; Pgp

Indexed keywords

CISPLATIN; DOCETAXEL; DOXORUBICIN; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; NSC23925; PACLITAXEL; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VINCRISTINE; (2-(4-METHOXYPHENYL)-4-QUINOLINYL)(2-PIPERIDINYL)METHANOL; ABCB1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; PIPERIDINE DERIVATIVE; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CROSS RESISTANCE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MOUSE MODEL; MULTIDRUG RESISTANCE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; FEMALE; METABOLISM; NUDE MOUSE; OVARIAN NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; P-GLYCOPROTEINS; PACLITAXEL; PIPERIDINES; QUINOLINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929938903     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2015.02.002     Document Type: Article

References (40)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Hirte HW. Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma. OncoTargets Ther 2013;6:427-35.
3. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;95:1320-9.
4. Chen X, Zhang J, Zhang Z, Li H, Cheng W, Liu J. Cancer stem cells, epithelialmesenchymal transition, and drug resistance in high-grade ovarian serous carcinoma. Hum Pathol 2013;44:2373-84.
5. Guppy AE, Nathan PD, Rustin GJ. Epithelial ovarian cancer: a review of current management. Clin Oncol R Coll Radiol (G B) 2005;17:399-411.
6. Higgins CF. Multiple molecular mechanisms for multidrug resistance transporters. Nature 2007;446:749-57.
7. Duan Z, Choy E, Hornicek FJ. NSC23925, identified in a high-throughput cell-based screen, reverses multidrug resistance. PLoS One 2009;4:e7415.
8. Kamazawa S, Kigawa J, Kanamori Y, Itamochi H, Sato S, Iba T, et al. Multidrug resistance gene-1 is a useful predictor of Paclitaxel-based chemotherapy for patients with ovarian cancer. Gynecol Oncol 2002;86:171-6.
9. Cocker HA, Tiffin N, Pritchard-Jones K, Pinkerton CR, Kelland LR. In vitro prevention of the emergence ofmultidrug resistance in a pediatric rhabdomyosarcoma cell line. Clin Cancer Res 2001;7:3193-8.
10. Yen WC, Corpuz MR, Prudente RY, Cooke TA, Bissonnette RP, Negro-Vilar A, et al. A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer. Clin Cancer Res 2004;10:8656-64.
11. Yen WC, Lamph WW. The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma. Mol Cancer Ther 2005;4:824-34.
12. Tooker P, Yen WC, Ng SC, Negro-Vilar A, Hermann TW. Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification. Cancer Res 2007;67:4425-33.
13. Sharma AK, Zhang L, Li S, Kelly DL, Alakhov VY, Batrakova EV, et al. Prevention of MDR development in leukemia cells bymicelle-forming polymeric surfactant. J Control Release 2008;131:220-7.
14. Caffrey PB, Frenkel GD. Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts in vivo. Cancer Chemother Pharmacol 2000;46:74-8.
15. Batrakova EV, Kelly DL, Li S, Li Y, Yang Z, Xiao L, et al. Alteration of genomic responses to doxorubicin and prevention ofMDR in breast cancer cells by a polymer excipient: pluronic P85. Mol Pharm 2006;3:113-23.
16. Caffrey PB, Frenkel GD. Treatment of human ovarian tumor xenografts with selenite prevents the melphalan-induced development of drug resistance. Anticancer Res 1998;18:3017-20.
17. Caffrey PB, Frenkel GD. Prevention of carboplatin-induced resistance in human ovarian tumor xenografts by selenite. Anticancer Res 2013;33:4249-54.
18. YenWC, LamphWW. A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer. Prostate 2006;66:305-16.
19. Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, et al. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 2010;116:1413-21.
20. Gandhi L, Harding MW, Neubauer M, Langer CJ, Moore M, Ross HJ, et al. A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer 2007;109:924-32.
21. Duan Z, Li X, Huang H, Yuan W, Zheng SL, Liu X, et al. Synthesis and evaluation of (2-(4-methoxyphenyl)-4-quinolinyl)(2-piperidinyl)methanol (NSC23925) isomers to reverse multidrug resistance in cancer. J Med Chem 2012;55:3113-21.
22. Yang X, Yang P, Shen J, Osaka E, Choy E, Cote G, et al. Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925. Br J Cancer 2014;110:2896-904.
23. Lamendola DE, Duan Z, Yusuf RZ, Seiden MV. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Cancer Res 2003;63:2200-5.
24. Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatininduced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007;13:4261-70.
25. Duan Z, Choy E, Jimeno JM, Cuevas Cdel M, Mankin HJ, Hornicek FJ. Diverse crossresistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines. Cancer Chemother Pharmacol 2009;63:1121-9.
26. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53: 615-27.
27. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATPdependent transporters. Nat Rev Cancer 2002;2:48-58.
28. Okugawa K, Kobayashi H, Hirakawa T, Sonoda T, Ogura T, Nakano H. In vivo establishment and characterization of a paclitaxel-resistant human ovarian cancer cell line showing enhanced growth properties and drug-resistance only in vivo. J Cancer Res Clin Oncol 2004;130:178-86.
29. Holleman A, Chung I, Olsen RR, Kwak B, Mizokami A, Saijo N, et al. miR-135a contributes to paclitaxel resistance in tumor cells both in vitro and in vivo. Oncogene 2011; 30:4386-98.
30. Starling JJ, Maciak RS, Hinson NA, Hoskins J, Laguzza BC, Gadski RA, et al. In vivo selection of human tumor cells resistant to monoclonal antibody-Vinca alkaloid immunoconjugates. Cancer Res 1990;50:7634-40.
31. Teicher BA, Herman TS, Holden SA, Wang YY, Pfeffer MR, Crawford JW, et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science (New York, N Y) 1990;247:1457-61.
32. Duan Z, Lamendola DE, Duan Y, Yusuf RZ, Seiden MV. Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines. Cancer Chemother Pharmacol 2005;55:277-85.
33. Yusuf RZ, Duan Z, Lamendola DE, Penson RT, Seiden MV. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets 2003;3:1-19.
34. Ozben T.Mechanisms and strategies to overcomemultiple drug resistance in cancer. FEBS Lett 2006;580:2903-9.
35. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-34.
36. Modok S, Mellor HR, Callaghan R. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. Curr Opin Pharmacol 2006;6: 350-4.
37. Shukla S, Ohnuma S, Ambudkar SV. Improving cancer chemotherapy with modulators of ABC drug transporters. Curr Drug Targets 2011;12:621-30.
38. Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, et al. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. Clin Cancer Res 2004;10:4724-33.
39. Seiden MV, Swenerton KD, Matulonis U, Campos S, Rose P, Batist G, et al. A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol 2002;86: 302-10.
40. Caffrey PB, Frenkel GD. Selenite enhances and prolongs the efficacy of cisplatin treatment of human ovarian tumor xenografts. In vivo (Athens, Greece) 2012;26:549-52.